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BACKGROUND / INTRODUCTION

DISCUSSION

METHODS
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A. The opportunity
for quality of care
improvements will be
assessed via
exploration of patient
care implications
associated with
current system
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B. A retrospective
chart review of patients
referred to ID department for
LD from 2015-2016 will be
carried out with RedCap and
Excel software, then analyzed
with
descriptive statistics.

Fig. 2: Deer Tick (PA’s vector for Lyme) relative size2

• Lyme disease (LD) is the most commonly
reported vector borne illness in the US3
• The bacteria responsible for LD, Borrelia
burgdorferi (Bb), is transmitted by an Ixodes
scapularis tick attachment lasting 36-48 hrs4
• The characteristic Erythema Migrans (EM)
Lesion (Bulls Eye or Target Rash) is present in
70% of infected individuals5
• Other symptoms can manifest days to months
after a tick bite5
• Symptomology is extremely variable per case
and ranges from fever and headache to
neurological and cardiac manifestations5
• Other conditions with nonspecific symptoms can
mimic Lyme Disease and result in LD
overdiagnosis. To ensure appropriate treatment,
a firm diagnosis is needed.5
• Lyme disease can be effectively diagnosed in a
case approached in a standardized,
comprehensive clinical approach. The CDC and
Infectious Diseases Society of America (IDSA)
provide evidence based guidelines to help
practitioners cut through the variability of this
disease. However, these guidelines are not
applied uniformly in Pennsylvania at this time.3
• PA has the highest number of reported LD cases
per state; reports of Lyme increased by 110%
from 2000-20156
• It’s estimated that Lyme Disease costs PA over
$74 million in lost productivity annually5
• Keeping these issues in mind, it’s important
to consider the opportunity for and potential
benefits of intervention and standardization
of Lyme Disease care within the LVHN.

RESULTS/DISCUSSION
As the retrospective study is still in progress, statistical results
are not yet available. However, conclusions can still be explored
from preliminary chart review and background research.
At this time, the most pertinent opportunities for
standardization and improved care include:

1

2

Collection of Patient History and Assessment of Risk
• Currently Lyme patient intake and consultation notes are
at unstandardized practitioner discretion
• Studies show factors like recreational activities and
symptom duration/evolution may be key considerations
for a LD diagnosis, yet are not consistently recorded5 7
• An incomplete and nonstandardized patient history may
result in imprecision with diagnosis and treatment plans.
Serological Testing
• The CDC recommended 2 tier testing algorithm for LD is
designed to optimize sensitivity and specificity4
• It’s composed of a nonspecific Enzyme-Linked
Immunosorbent Assay confirmed by a specialized
Western Blot4
• Studies reveal this system to be ~98.5% and ~90%
sensitive in late and early stage LD respectively8
• Potential errors in application of this system include:
-performing the 2nd tier of the test and not the 1st,
(doubling the likelihood of a false positive)
-incorrect timeframe of testing
-performing testing when not clinically indicated8
• The FDA predicts the direct medical cost of
inaccurate testing to be $1,226 a case (accounting for
visits, treatments, and testing)9

Treatment and Administration of Antibiotics
• Despite established professional society guidelines,
treatment may be variable. Potential error includes:
-prolonged antibiotic treatment
-antibiotics without shown efficacy against Bb.
-unstudied alternative treatments4
Patients that receive unneeded antibiotic treatment:
- face unnecessary health risks associated
with the drug, from minor adverse events (ie
diarrhea) to major ones (ie septic shock)10
Patients that receive delayed antibiotic treatment:
- are at greater risk for disease complications4
- late-stage LD direct healthcare costs are ~$916
more compared to early-stage LD costs (average
annual LD medical costs being $2,968)11 12

1248
10x
25%

Number reported Lyme cases in the Lehigh Valley and
surrounding counties in 2015, 62.3% increase since 20146
CDC’s prediction that actual cases of Lyme are 10x that
reported, suggesting there could be as many as 12,480
annual cases in the LV5
Percent of referrals to LVHN’s Department of Infectious
Diseases in 2016 that were for Lyme Disease.13

CONCLUSION
Considering the increasing presence of Lyme Disease in
the LVHN region, as well as the financial and health risks
associated with mistreatment/misdiagnosis of this disease,
there is an enormous opportunity for quality improvement.
• A retrospective chart review will allow better insight on
the state of the current system
• Potential future interventions include development of
targeted LD training programs for practitioners, EPIC
prompts during a consult, and enrollment
questionnaires.
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